title: Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers.
abstract: Proline oxidase (POX), a flavoenzyme localized at the inner mitochondrial membrane, catalyzes the first step of proline degradation by converting proline to pyrroline-5-carboxylate (P5C). POX is markedly elevated during p53-induced apoptosis and generates proline-dependent reactive oxygen species (ROS), specifically superoxide radicals, to induce apoptosis through both mitochondrial and death receptor pathways. These previous studies also showed suppression of the mitogen-activated protein kinase pathway leading us to broaden our exploration of proliferative signaling. In our current report, we used DLD-1 colorectal cancer cells stably transfected with the POX gene under the control of a tetracycline-inducible promoter and found that three pathways which cross talk with each other were downregulated by POX: the cyclooxygenase-2 (COX-2) pathway, the epidermal growth factor receptor (EGFR) pathway and the Wnt/beta-catenin pathway. First, POX markedly reduced COX-2 expression, suppressed the production of prostaglandin E2 (PGE(2)) and importantly, the growth inhibition by POX was partially reversed by treatment with PGE(2.) Phosphorylation of EGFR was decreased with POX expression and the addition of EGF partially reversed the POX-dependent downregulation of COX-2. Wnt/beta-catenin signaling was decreased by POX in that phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) was decreased on the one hand and phosphorylation of beta-catenin was increased on the other. There changes led to decreased accumulation of beta-catenin and decreased beta-catenin/TCF/LEF-mediated transcription. Our newly described POX-mediated suppression of proliferative signaling together with the previously reported induction of apoptosis suggested that POX could function as a tumor suppressor. Indeed, in human colorectal tissue samples, immunohistochemically-monitored POX was dramatically decreased in tumors compared with normal counterparts. Thus, POX metabolism of substrate proline affects multiple signaling pathways, modulating both apoptosis and tumor growth, and could be an attractive target to metabolically control the cancer phenotypes.
authors.affiliation: 1Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: G L
authors.initials: GL
authors.lastname: Borchert
authors.forename: A
authors.initials: A
authors.lastname: Surazynski
authors.forename: J M
authors.initials: JM
authors.lastname: Phang
mesh_terms: D017209:Apoptosis; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000235:genetics; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism*; D015232:Dinoprostone / Q000378:metabolism*; D015536:Down-Regulation; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D038362:Glycogen Synthase Kinase 3 / Q000235:genetics / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D024101:Mitochondrial Proteins / Q000096:biosynthesis* / Q000235:genetics; D010766:Phosphorylation; D011392:Proline / Q000235:genetics / Q000378:metabolism; D011394:Proline Oxidase / Q000096:biosynthesis* / Q000235:genetics; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction; D014158:Transcription, Genetic; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D051153:Wnt Proteins / Q000235:genetics / Q000378:metabolism; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism
chemical_list: D024101:Mitochondrial Proteins; D017382:Reactive Oxygen Species; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D051153:Wnt Proteins; D051176:beta Catenin; D011392:Proline; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011394:Proline Oxidase; C512478:EGFR protein, human; D066246:ErbB Receptors; C000605506:GSK3B protein, human; D000071679:Glycogen Synthase Kinase 3 beta; D038362:Glycogen Synthase Kinase 3; D015232:Dinoprostone
references.citation: J Biol Chem. 2004 Apr 30;279(18):18694-700
references.pmid: 14976201
references.citation: Arch Biochem Biophys. 1986 Jul;248(1):166-74
references.pmid: 3729412
references.citation: Oncogene. 2006 Sep 14;25(41):5640-7
references.pmid: 16619034
references.citation: J Biol Chem. 2005 Jul 15;280(28):26565-72
references.pmid: 15899904
references.citation: Dev Cell. 2006 Jun;10(6):687-8
references.pmid: 16740470
references.citation: J Biol Chem. 2006 Jan 27;281(4):2044-52
references.pmid: 16303758
references.citation: Cancer Res. 2005 Sep 15;65(18):8242-9
references.pmid: 16166300
references.citation: J Clin Invest. 1997 Sep 15;100(6):1325-9
references.pmid: 9294096
references.citation: Curr Pharm Des. 2004;10(6):635-46
references.pmid: 14965326
references.citation: Nat Rev Cancer. 2001 Oct;1(1):11-21
references.pmid: 11900248
references.citation: Cell. 1996 Oct 18;87(2):159-70
references.pmid: 8861899
references.citation: Acta Neuropathol. 2002 Apr;103(4):415-20
references.pmid: 11904762
references.citation: J Biol Chem. 2000 Apr 21;275(16):11750-7
references.pmid: 10766797
references.citation: J Biol Chem. 1988 Sep 15;263(26):13083-9
references.pmid: 2458343
references.citation: Hum Mol Genet. 1999 Dec;8(13):2359-68
references.pmid: 10556283
references.citation: Cell. 1996 Nov 29;87(5):803-9
references.pmid: 8945508
references.citation: J Biol Chem. 2004 Apr 2;279(14):14287-93
references.pmid: 14742435
references.citation: Trends Cell Biol. 2007 Jun;17(6):286-91
references.pmid: 17481900
references.citation: Clin Transl Oncol. 2006 Oct;8(10):711-6
references.pmid: 17074669
references.citation: Cancer Res. 1998 Feb 1;58(3):409-12
references.pmid: 9458081
references.citation: Carcinogenesis. 2005 Aug;26(8):1335-42
references.pmid: 15817612
references.citation: Am J Med Genet A. 2006 Apr 15;140(8):906-9
references.pmid: 16532473
references.citation: J Clin Oncol. 2005 Jan 10;23(2):254-66
references.pmid: 15637389
references.citation: Adv Anat Pathol. 2006 Sep;13(5):270-4
references.pmid: 16998321
references.citation: World J Gastroenterol. 2007 Jul 28;13(28):3784-91
references.pmid: 17657831
references.citation: Nat Rev Cancer. 2007 Feb;7(2):139-47
references.pmid: 17218951
references.citation: J Biol Chem. 2005 Aug 12;280(32):29346-54
references.pmid: 15914462
references.citation: Nature. 1997 Sep 18;389(6648):300-5
references.pmid: 9305847
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: Mol Biol Cell. 2005 Dec;16(12):5579-91
references.pmid: 16195339
references.citation: Cancer Res. 2001 Mar 1;61(5):1810-5
references.pmid: 11280728
references.citation: Science. 2005 Dec 2;310(5753):1504-10
references.pmid: 16293724
references.citation: J Biol Chem. 2003 Sep 12;278(37):35451-7
references.pmid: 12824187
references.citation: Cancer Res. 2003 Feb 1;63(3):728-34
references.pmid: 12566320
references.citation: Biochim Biophys Acta. 2000 Mar 27;1470(2):M69-78
references.pmid: 10722929
references.citation: Science. 2007 Nov 16;318(5853):1108-13
references.pmid: 17932254
references.citation: Int J Cancer. 2008 Mar 15;122(6):1435-40
references.pmid: 17999410
references.citation: J Biol Chem. 2003 Mar 14;278(11):9784-9
references.pmid: 12514185